Coming up at 6:00 p.m. EST on Monday, Dec. 8 at #ASH25, Dr. Elizabeth Bouchard and Dr. Kara Kelly present findings on advancing strategies to improve chemotherapy adherence in young children with ALL (Abstract 4618, West Halls B3–B4).

Coming up at 6:00 p.m. EST on Monday, Dec. 8 at #ASH25, Allan Pavy, PhD, presents new data from the Davila Lab at Roswell Park on IL-2 mutein–mediated improvement of CAR T-cell function in relapsed/refractory diffuse B-cell lymphoma (Abstract 7239, West Halls B3-B4).

Starting soon at #ASH25, Dr. Eunice Wang share findings on crenolanib and ziftomenib combinations targeting multiple mutations, which show promise for AML patients with relapse disease. (Chaplin Theater, W320).

Learn more: www.roswellpark.org/newsroom/202...

Hear from some of our experts in hematology and oncology on why conferences like #ASH25 are so important. #fight4hematology

Coming up at 1:15 p.m., Dr. Meredith Stone presents findings from the Davila Lab Group at Roswell Park on CAR T cell-driven induction of iNOS in tumor-associated macrophages, which promote CAR T-cell resistance in B cell lymphoma. (Oral Abstract #13711 in Tangerine Ballroom F1) #ASH25

Coming up this evening at #ASH25, senior author, Dr. Pamela Sung, will share findings (abstract 1911) on combining FLT3 and EZH1/2 inhibitors in #AML models. Starting at 5:30 p.m. in West Hall B3-B4.

Exciting career opportunities are happening at Roswell Park! Stop by booth #2179 to see how you could be a part of the hem-onc and cell therapy innovations happening in Buffalo! #ASH25

Learn more and continue the conversations on cell therapy advancements by stopping by our booth (#2179). Many of Roswell Park’s staff will be there throughout the conference!